FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045457068> ?p ?o ?g. }

• W2045457068 endingPage "115" @default.
• W2045457068 startingPage "103" @default.
• W2045457068 abstract "Following oral administration of empagliflozin (1000 mg/kg/day) to male and female CD-1 mice for 2 years, renal tubular injury was identified in male mice. Renal injury was not detected in male mice (≤300 mg/kg/day), in female mice (1000 mg/kg/day), or in male or female Han Wistar rats (700 mg/kg/day). Using transfected HEK293 cells and Xenopus oocytes, empagliflozin was found to be a substrate of various mouse and rat organic anion transporters (oat/Oat) and organic anion transporting polypeptide (oatp/Oatp) transporters: mouse oat3, rat Oat3, mouse oatp1a1, and rat Oatp1a1. However, using isolated kidney slices from male and female mice and rats, no sex-based difference in the extent of uptake of empagliflozin occurred. Metabolism studies using hepatic and renal microsomes from male and female mice, rats, and humans revealed a hemiacetal metabolite of empagliflozin (M466/2), predominantly formed in male mouse kidney microsomes. Formation of M466/2 in male mouse kidney microsomes was 31-fold higher compared to that in female mouse kidney microsomes and was ∼29- and ∼20-fold higher compared to that in male and female mouse liver microsomes, respectively. M466/2 is unstable and degrades to form a phenol metabolite (M380/1) and 4-hydroxycrotonaldehyde (4-OH CTA). Formed 4-OH CTA was trapped by reduced GSH, and the structure of the GSH adduct was confirmed by mass spectrometry. Stoichiometric formation of M380/1 from M466/2 was observed (93-96% at 24 h); however, formation of 4-OH CTA was considerably lower (∼17.5% at 40 h), which is consistent with 4-OH CTA being a highly reactive species. These data represent a highly selective tissue-, species-, and sex-specific lesion in male CD-1 mice associated with a cytotoxic metabolite product, 4-OH CTA. In humans, glucuronidation of empagliflozin is the most prevalent metabolic pathway, and oxidation is a minor pathway. Thus, renal toxicity due to the formation of 4-OH CTA from empagliflozin is not expected in humans." @default.
• W2045457068 created "2016-06-24" @default.
• W2045457068 creator A5000047737 @default.
• W2045457068 creator A5012071817 @default.
• W2045457068 creator A5024345070 @default.
• W2045457068 creator A5024576356 @default.
• W2045457068 creator A5028198652 @default.
• W2045457068 creator A5067141512 @default.
• W2045457068 creator A5089659933 @default.
• W2045457068 date "2015-01-05" @default.
• W2045457068 modified "2023-10-11" @default.
• W2045457068 title "Sex-, Species-, and Tissue-Specific Metabolism of Empagliflozin in Male Mouse Kidney Forms an Unstable Hemiacetal Metabolite (M466/2) That Degrades to 4-Hydroxycrotonaldehyde, a Reactive and Cytotoxic Species" @default.
• W2045457068 cites W1512501096 @default.
• W2045457068 cites W1971901938 @default.
• W2045457068 cites W1979232837 @default.
• W2045457068 cites W1992983589 @default.
• W2045457068 cites W1999814147 @default.
• W2045457068 cites W2005693539 @default.
• W2045457068 cites W2030219661 @default.
• W2045457068 cites W2047706200 @default.
• W2045457068 cites W2048192376 @default.
• W2045457068 cites W2068880247 @default.
• W2045457068 cites W2077007445 @default.
• W2045457068 cites W2092435827 @default.
• W2045457068 cites W2096294438 @default.
• W2045457068 cites W2096565553 @default.
• W2045457068 cites W2101634894 @default.
• W2045457068 cites W2103726108 @default.
• W2045457068 cites W2106535916 @default.
• W2045457068 cites W2119981294 @default.
• W2045457068 cites W2124322010 @default.
• W2045457068 cites W2128219379 @default.
• W2045457068 cites W2129852694 @default.
• W2045457068 cites W2131146008 @default.
• W2045457068 cites W2134855422 @default.
• W2045457068 cites W2135290874 @default.
• W2045457068 cites W2137107263 @default.
• W2045457068 cites W2138084859 @default.
• W2045457068 cites W2141228342 @default.
• W2045457068 cites W2145372024 @default.
• W2045457068 cites W2148409401 @default.
• W2045457068 cites W2154543112 @default.
• W2045457068 cites W2156069682 @default.
• W2045457068 cites W2163621576 @default.
• W2045457068 cites W2164029851 @default.
• W2045457068 cites W2332239990 @default.
• W2045457068 doi "https://doi.org/10.1021/tx500380t" @default.
• W2045457068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25489797" @default.
• W2045457068 hasPublicationYear "2015" @default.
• W2045457068 type Work @default.
• W2045457068 sameAs 2045457068 @default.
• W2045457068 citedByCount "28" @default.
• W2045457068 countsByYear W20454570682015 @default.
• W2045457068 countsByYear W20454570682016 @default.
• W2045457068 countsByYear W20454570682017 @default.
• W2045457068 countsByYear W20454570682018 @default.
• W2045457068 countsByYear W20454570682019 @default.
• W2045457068 countsByYear W20454570682020 @default.
• W2045457068 countsByYear W20454570682021 @default.
• W2045457068 countsByYear W20454570682022 @default.
• W2045457068 countsByYear W20454570682023 @default.
• W2045457068 crossrefType "journal-article" @default.
• W2045457068 hasAuthorship W2045457068A5000047737 @default.
• W2045457068 hasAuthorship W2045457068A5012071817 @default.
• W2045457068 hasAuthorship W2045457068A5024345070 @default.
• W2045457068 hasAuthorship W2045457068A5024576356 @default.
• W2045457068 hasAuthorship W2045457068A5028198652 @default.
• W2045457068 hasAuthorship W2045457068A5067141512 @default.
• W2045457068 hasAuthorship W2045457068A5089659933 @default.
• W2045457068 hasConcept C126322002 @default.
• W2045457068 hasConcept C134018914 @default.
• W2045457068 hasConcept C181199279 @default.
• W2045457068 hasConcept C185592680 @default.
• W2045457068 hasConcept C2777477808 @default.
• W2045457068 hasConcept C2780091579 @default.
• W2045457068 hasConcept C55493867 @default.
• W2045457068 hasConcept C71924100 @default.
• W2045457068 hasConcept C86803240 @default.
• W2045457068 hasConcept C87644729 @default.
• W2045457068 hasConcept C98274493 @default.
• W2045457068 hasConceptScore W2045457068C126322002 @default.
• W2045457068 hasConceptScore W2045457068C134018914 @default.
• W2045457068 hasConceptScore W2045457068C181199279 @default.
• W2045457068 hasConceptScore W2045457068C185592680 @default.
• W2045457068 hasConceptScore W2045457068C2777477808 @default.
• W2045457068 hasConceptScore W2045457068C2780091579 @default.
• W2045457068 hasConceptScore W2045457068C55493867 @default.
• W2045457068 hasConceptScore W2045457068C71924100 @default.
• W2045457068 hasConceptScore W2045457068C86803240 @default.
• W2045457068 hasConceptScore W2045457068C87644729 @default.
• W2045457068 hasConceptScore W2045457068C98274493 @default.
• W2045457068 hasIssue "1" @default.
• W2045457068 hasLocation W20454570681 @default.
• W2045457068 hasLocation W20454570682 @default.
• W2045457068 hasOpenAccess W2045457068 @default.
• W2045457068 hasPrimaryLocation W20454570681 @default.
• W2045457068 hasRelatedWork W2020959757 @default.
• W2045457068 hasRelatedWork W2030400955 @default.

• next